TANVEX
associated with 8 other trademarks
Anti-arthritis preparations; anti-inflammatory agent; anticancer drug; antirheumatic preparations; medicines for human purposes for treating diseases ...

Words that describe this trademark:

western medicine  anticancer drug  human purposes  agent  antirheumatic  purposes  antiinflammatory  antiarthritis  drug  medicines 

Serial Number:

87323906

Mark:

TANVEX

Status:

Registered

Status Date:

05-25-2021

Filing Date:

Registration Number:

6358665

Registration Date:

05-25-2021

Goods and Services:

Anti-arthritis preparations; anti-inflammatory agent; anticancer drug; antirheumatic preparations; medicines for human purposes for treating diseases and medical conditions in the fields of dermatology, gastroenterology, hematology, infectious disease, oncology, and rheumatology, namely, neutropenia, breast cancer, gastric cancer, colorectal cancer, lung cancer, glioblastoma, carcinoma, arthritis, Crohn's disease, plaque psoriasis, asthma, chronic idiopathic urticaria, pararoxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and ankylosing spondylitis; western medicines for treating diseases and medical conditions in the fields of dermatology, gastroenterology, hematology, infectious disease, oncology, and rheumatology, namely, neutropenia, breast cancer, gastric cancer, colorectal cancer, lung cancer, glioblastoma, carcinoma, arthritis, Crohn's disease, plaque psoriasis, asthma, chronic idiopathic urticaria, pararoxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and ankylosing spondylitis; medicinal agent for human use, namely, medicinal herbal preparations; biological preparations for medical purposes for treating diseases and medical conditions in the fields of dermatology, gastroenterology, hematology, infectious disease, oncology, and rheumatology, namely, neutropenia, breast cancer, gastric cancer, colorectal cancer, lung cancer, glioblastoma, carcinoma, arthritis, Crohn's disease, plaque psoriasis, asthma, chronic idiopathic urticaria, pararoxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and ankylosing spondylitis; haematogen, namely, blood substitutes for human use; chemical preparations for medical purposes for treating diseases and medical conditions in the fields of dermatology, gastroenterology, hematology, infectious disease, oncology, and rheumatology, namely, neutropenia, breast cancer, gastric cancer, colorectal cancer, lung cancer, glioblastoma, carcinoma, arthritis, Crohn's disease, plaque psoriasis, asthma, chronic idiopathic urticaria, pararoxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and ankylosing spondylitis; pharmaceutical drugs for treating diseases and medical conditions in the fields of dermatology, gastroenterology, hematology, infectious disease, oncology, and rheumatology, namely, neutropenia, breast cancer, gastric cancer, colorectal cancer, lung cancer, glioblastoma, carcinoma, arthritis, Crohn's disease, plaque psoriasis, asthma, chronic idiopathic urticaria, pararoxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and ankylosing spondylitis; pharmaceutical preparations for treating diseases and medical conditions in the fields of dermatology, gastroenterology, hematology, infectious disease, oncology, and rheumatology, namely, neutropenia, breast cancer, gastric cancer, colorectal cancer, lung cancer, glioblastoma, carcinoma, arthritis, Crohn's disease, plaque psoriasis, asthma, chronic idiopathic urticaria, pararoxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and ankylosing spondylitis

Mark Description:

The mark consists of the word "TANVEX" in the color light blue in stylized typeface.

Class:

Pharmaceutical and veterinary preparations

Type of Mark:

Trademark

Published for Opposition Date:

03-09-2021

Mark Drawing Status:

Words, Letters, and/or Numbers in Stylized From

Abandon Date:

N/A

Business Name:

BAKER & MCKENZIE LLP

Correspondent Name:

Recent Trademark filings by this company